Cargando…
Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study
OBJECTIVE: To monitor the adverse drug reactions (ADRs) associated with imatinib treatment in patients with chronic myeloid leukemia (CML) in a tertiary care hospital. MATERIALS AND METHODS: The study was carried out by the Departments of Pharmacology and Medical Oncology, Jawaharlal Institute of Po...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319245/ https://www.ncbi.nlm.nih.gov/pubmed/25709349 http://dx.doi.org/10.4103/0976-500X.149141 |
_version_ | 1782355929659867136 |
---|---|
author | Francis, Jose Palaniappan, Muthiah Dubashi, Biswajit Pradhan, Suresh Chandra Chandrasekaran, Adithan |
author_facet | Francis, Jose Palaniappan, Muthiah Dubashi, Biswajit Pradhan, Suresh Chandra Chandrasekaran, Adithan |
author_sort | Francis, Jose |
collection | PubMed |
description | OBJECTIVE: To monitor the adverse drug reactions (ADRs) associated with imatinib treatment in patients with chronic myeloid leukemia (CML) in a tertiary care hospital. MATERIALS AND METHODS: The study was carried out by the Departments of Pharmacology and Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India. The study was carried out from March 2012 to February 2014. The ADRs were reported in a suspected Adverse Drug Reaction Reporting form, provided by the Central Drugs Standard Control Organization (CDSCO), Ministry of Health and Family Welfare, Government of India. The ADRs were analyzed for their pattern, causality and severity. RESULTS: A total of 326 ADRs from 81 patients were reported during the study period. The hematological toxicities were much more prominent than the non-hematological toxicities in this study. The prevalence of thrombocytopenia (21.17%) was higher compared with other reactions. Further analysis showed that most of the ADRs were mild to moderate in nature. The causality assessment revealed that the majority of the ADRs belonged to the possible category. CONCLUSION: The present study in a tertiary care hospital suggests that hematological toxicities are predominant in CML patients treated with imatinib mesylate. The blood and lymphatic system (38.96%) was the most affected, with imatinib therapy and thrombocytopenia (21.17%) being the most commonly encountered ADRs in the present study. Thorough monitoring of ADRs is warranted for better treatment outcomes. |
format | Online Article Text |
id | pubmed-4319245 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-43192452015-02-23 Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study Francis, Jose Palaniappan, Muthiah Dubashi, Biswajit Pradhan, Suresh Chandra Chandrasekaran, Adithan J Pharmacol Pharmacother Research Paper OBJECTIVE: To monitor the adverse drug reactions (ADRs) associated with imatinib treatment in patients with chronic myeloid leukemia (CML) in a tertiary care hospital. MATERIALS AND METHODS: The study was carried out by the Departments of Pharmacology and Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India. The study was carried out from March 2012 to February 2014. The ADRs were reported in a suspected Adverse Drug Reaction Reporting form, provided by the Central Drugs Standard Control Organization (CDSCO), Ministry of Health and Family Welfare, Government of India. The ADRs were analyzed for their pattern, causality and severity. RESULTS: A total of 326 ADRs from 81 patients were reported during the study period. The hematological toxicities were much more prominent than the non-hematological toxicities in this study. The prevalence of thrombocytopenia (21.17%) was higher compared with other reactions. Further analysis showed that most of the ADRs were mild to moderate in nature. The causality assessment revealed that the majority of the ADRs belonged to the possible category. CONCLUSION: The present study in a tertiary care hospital suggests that hematological toxicities are predominant in CML patients treated with imatinib mesylate. The blood and lymphatic system (38.96%) was the most affected, with imatinib therapy and thrombocytopenia (21.17%) being the most commonly encountered ADRs in the present study. Thorough monitoring of ADRs is warranted for better treatment outcomes. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4319245/ /pubmed/25709349 http://dx.doi.org/10.4103/0976-500X.149141 Text en Copyright: © Journal of Pharmacology and Pharmacotherapeutics http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Paper Francis, Jose Palaniappan, Muthiah Dubashi, Biswajit Pradhan, Suresh Chandra Chandrasekaran, Adithan Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study |
title | Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study |
title_full | Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study |
title_fullStr | Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study |
title_full_unstemmed | Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study |
title_short | Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study |
title_sort | adverse drug reactions of imatinib in patients with chronic myeloid leukemia: a single-center surveillance study |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319245/ https://www.ncbi.nlm.nih.gov/pubmed/25709349 http://dx.doi.org/10.4103/0976-500X.149141 |
work_keys_str_mv | AT francisjose adversedrugreactionsofimatinibinpatientswithchronicmyeloidleukemiaasinglecentersurveillancestudy AT palaniappanmuthiah adversedrugreactionsofimatinibinpatientswithchronicmyeloidleukemiaasinglecentersurveillancestudy AT dubashibiswajit adversedrugreactionsofimatinibinpatientswithchronicmyeloidleukemiaasinglecentersurveillancestudy AT pradhansureshchandra adversedrugreactionsofimatinibinpatientswithchronicmyeloidleukemiaasinglecentersurveillancestudy AT chandrasekaranadithan adversedrugreactionsofimatinibinpatientswithchronicmyeloidleukemiaasinglecentersurveillancestudy |